CIDE-B Antibody
| Code | Size | Price |
|---|
| PSI-2321-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-2321-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
CIDE-B Antibody: CIDE-B, AI790179, 1110030C18Rik, Cell death activator CIDE-B, Cell death-inducing DFFA-like effector B
Application Note:
CIDE-B antibody can be used for detection of CIDE-B by Western blot at 0.5 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
CIDE-B Antibody: Apoptosis is related to many diseases and induced by a family of cell death receptors and their ligands. Cell death signals are transduced by death domain containing adapter molecules and members of the caspase family of proteases. These death signals finally cause the degradation of chromosomal DNA by activated DNase. DFF45/ICAD has been identified as inhibitor of caspase activated DNase DFF40/CAD. DFF45 related proteins CIDE-A and CIDE-B (for cell death-inducing DFF-like effector A and B) were recently identified. CIDE contains a new type of domain termed CIDE-N, which has high homology with the regulatory domains of DFF45/ICAD and DFF40/CAD. Expression of CIDE-B induces apoptosis, which is inhibited by DFF45. CIDE-B is a DFF45-inhibitable effector that promotes cell death and DNA fragmentation. CIDE-B is expressed mainly in liver and at lower levels in spleen, kidney, peripheral blood lymphocytes and bone marrow.
Background References:
- Inohara N, Koseki T, Chen S,et al. CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J. 1998; 17:2526-33.
- Inohara N, Koseki T, Chen S, et al. Identification of regulatory and catalytic domains in the apoptosis nuclease DFF40/CAD. J. Biol. Chem.1999; 274:270-4.
Buffer:
CIDE-B Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (86%)
Immunogen:
CIDE-B antibody was raised against a peptide corresponding to 14 amino acids near the center of human CIDE-B.
The immunogen is located within amino acids 100 - 150 of CIDE-B.
The immunogen is located within amino acids 100 - 150 of CIDE-B.
NCBI Gene ID #:
27141
NCBI Official Name:
cell death-inducing DFFA-like effector b
NCBI Official Symbol:
CIDEB
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AF218586
Protein GI Number:
6746626
Purification:
CIDE-B Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
CIDE-B antibody has no cross activity to CIDE-A.
Swissprot #:
Q9UHD4
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | CIDE-B Peptide | PSI-2321P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|